Contract Manufacturing Trends Transforming the Biopharmaceutical Industry The biopharmaceutical contract manufacturing market is experiencing rapid expansion as pharmaceutical and biotechnology companies increasingly outsource complex production processes to specialized partners. Driven by the rising demand for biologics, biosimilars, and personalized therapies, contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) are becoming critical enablers of innovation and scalability across the global biopharma value chain. For More: https://www.theinsightpartners.com/reports/biopharmaceutical-contract-manufacturing-market The market is projected to grow from US$ 40.99 billion in 2024 to US$ 101.05 billion by 2031, registering a strong CAGR of 13.8% during 2025–2031. This growth trajectory reflects structural shifts in drug development, manufacturing technologies, and global supply chain strategies.